Pancreatic neuroendocrine tumours (PanNETs) are rare diseases and a good example of how research is not only feasible, but also of crucial importance in the scenario of rare tumours. Many clinical trials have been performed over the past two decades expanding therapeutic options for patients with advanced PanNETs. Adequate management relies on optimal selection of treatment, which may be challenging for clinicians due to the fact that multiple options of therapy are currently available. A number of therapies already exist, which are supported by data from phase III studies, including somatostatin analogues and targeted therapies (sunitinib and everolimus). In addition, chemotherapy remains an option, with temozolomide and capecitabine being one of the most popular doublets to use. Peptide receptor radionuclide therapy was successfully implemented in patients with well-differentiated gastro-entero-pancreatic neuroendocrine tumours, but with certain questions waiting to be solved for the management of PanNETs. Finally, the role of immunotherapy is still poorly understood. In this review, the data supporting current systemic treatment options for locally advanced or metastatic PanNETs are summarized. Strategies for treatment selection in patients with PanNETs based on patient, disease, or drug characteristics is provided, as well as a summary of current evidence on prognostic and predictive biomarkers. Future perspectives are discussed, focusing on current and forthcoming challenges and unmet needs of patients with these rare tumours.
The most important prognostic factors for breast cancer are the size of primary tumor and axillary lymph node status. Role of scintimammography with the cationic lipophilic 99mTc-Tetrofosmin and 99mTc-Sestamibi in preoperative evaluation and post-treatment follow-up of patients with breast cancer is well known. The added diagnostic value of SPECT-CT has recently been investigated. Scintigraphy provides a description of function or process whereas CT depicts the precise localization and type of morphological changes that have occurred in the lesions. Combined SPECT-CT imaging enables to localize positive primary tumors and/or loco-regional lymph nodes; to evaluate effect of neoadjuvant chemotherapy in locally advanced and non-operable breast tumors. SPECT-CT studies are useful in post-therapeutic follow-up of patients to visualize suspicious local recurrence, lymphadenopathy and disease extension. CT part of the study can increase the specificity of SPECT by more accurate anatomical assessment of the sites of abnormal activity with unclear character such as radiation pulmonitis, postoperative parenchymal changes, fibrocystic changes etc. According to the results reported in literature, all the axillary metastatic nodes that were false negative on SPECT image were non-palpable, small lesion size (<10 mm) with partial metastatic involvement or micrometastases in most cases. Lymphatic mapping of SLNs is now routinely done in breast cancer patients for correct N-staging. SPECT-CT has been used for clear depiction of the SLNs to provide the useful information for intraoperative gamma-probe detection in cases that are difficult to interpret planar images, in cases with unusual drainage or in cases of nonvisualization. SPECT-CT scintimammogarphy is preferable in terms of physical characteristic, execution time and cost-effectiveness, thus suggesting wider application of this procedure. SPECT-CT is a potential new tool for LN localization and radioguided surgery in the coming years
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.